Reports Q3 revenue $240M, consensus $268.3M. "For more than 20 years, Emergent has been a dependable partner to customers, including the U.S. and allied governments, in helping prepare for public health threats through our products, services, and development programs," said Robert Kramer, president and CEO. "As we continue to strengthen our operations, be guided by financial discipline, and evaluate opportunities for growth, we remain confident in our ability to deliver results for our patients, customers, and shareholders."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EBS:
- Emergent BioSolutions Reports Financial Results For Third Quarter 2022
- Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
- Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
- Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
